Merck KGaA confirms leadership team appointments
pharmafile | June 20, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â EMD Serono, Merck KGaA, SeronoÂ
The subsidiary of Merck KGaA named EMD Serono has announced several appointments to its leadership team.
The appointments include: Allene Diaz (pictured), senior VP, head of US Oncology; Evan Lippman, senior VP of Neurodegenerative Diseases and Rheumatology; Rami Levin, VP of Marketing, Neurodegenerative Diseases and Rheumatology; and Craig Millian, senior VP, head of US Fertility, Metabolic Endocrinology and HIV.
“It brings me great pleasure to announce the appointments of Craig, Allene and Rami and to welcome Evan to our organisation,” said James Hoyes, president of EMD Serono. “Their knowledge, experience and global perspective will strengthen EMD Serono as a leader in biopharmaceuticals in the US. Furthermore, these appointments underscore our commitment to recruiting top external talent and promoting great talent from within.”
Diaz brings more than 25 years of both US-based and international industry experience to the newly created role. She will be responsible for leading the commercial efforts for EMD Serono’s US Oncology business.
Lippman comes from AstraZeneca, where he most recently served as executive director of the company’s Crestor brand, following a number of leadership roles, including executive director and head of US Business Development.
Reporting to Lippman will be Levin who has been with Merck Serono since 1998, most recently as chairman and managing director of Merck AB in Sweden and Iceland.
Millian joins EMD Serono after taking over his role on an ad-interim basis earlier this year. Prior to his new role, he led the marketing organisation supporting brands across reproductive health, growth hormone deficiency and HIV-related metabolic disorders as VP of Endocrinology Marketing.
Diaz, Lippman and Millian will serve as members of EMD Serono’s executive committee.
Related Content
Exscientia enters AI drug discovery collaboration with Merck KGaA
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …
Merck KGaA’s cancer drug Bavencio gets EU approval
The EC has approved Merck KGaA’s BAVENCIO (avelumab) as monotherapy for the first-line maintenance treatment …
Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO
German pharma firm Merck KGaA has taken the decision to appoint its first female Chief …
